{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:07:18Z","timestamp":1785215238144,"version":"3.55.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chung-Ang University Medical Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Doxepin, a tricyclic antidepressant, exhibits substantial interindividual variability in pharmacokinetics, mainly attributable to genetic polymorphisms of cytochrome P450 (CYP) enzymes, particularly CYP2D6. Such variability may lead to clinically relevant differences in drug exposure, therapeutic response, and adverse effects when doxepin is used for antidepressant therapy. The present study aimed to develop and validate physiologically based pharmacokinetic (PBPK) models of doxepin and its active metabolite,\n                    <jats:italic>N<\/jats:italic>\n                    -desmethyldoxepin, incorporating CYP2D6 genetic polymorphisms to support precision pharmacotherapy. PBPK models were constructed using PK-Sim\n                    <jats:sup>\u00ae<\/jats:sup>\n                    (version 12.0) based on published clinical pharmacokinetic and pharmacogenomic data obtained after oral administration of doxepin. Model development was performed in a non-genotyped population. Subsequently, it extended to CYP2D6 ultra-rapid (UM), normal (NM), intermediate (IM), and poor metabolizer (PM) phenotypes by integrating genotype-specific metabolic activity. Model performance was evaluated by comparing predicted plasma concentration\u2013time profiles, area under the concentration\u2013time curve (AUC), and maximum plasma concentration (C\n                    <jats:sub>max<\/jats:sub>\n                    ) with observed clinical data. The model's predictive capability was further assessed using goodness-of-fit analysis, visual predictive checks, and geometric mean fold error (GMFE). The PBPK models adequately reproduced the observed pharmacokinetics of doxepin and\n                    <jats:italic>N<\/jats:italic>\n                    -desmethyldoxepin, with most predicted AUC and C\n                    <jats:sub>max<\/jats:sub>\n                    values falling within a twofold error range across both non-genotyped and CYP2D6-genotyped populations. Simulations demonstrated an apparent genotype-dependent increase in doxepin exposure as CYP2D6 metabolic capacity decreased, consistent with clinical observations. Similarly,\n                    <jats:italic>N<\/jats:italic>\n                    -desmethyldoxepin exposure showed an inverse relationship with CYP2D6 activity, reflecting differences in metabolite formation and elimination. Despite the limited availability of genotype-specific concentration\u2013time data for the metabolite, the model captured observed exposure trends, supporting its mechanistic plausibility. In conclusion, a PBPK framework integrating CYP2D6 genetic polymorphisms was successfully developed for doxepin and its active metabolite. The model reliably predicts genotype-dependent pharmacokinetic variability and provides a mechanistic basis for individualized dose optimization. This PBPK approach may serve as a valuable tool to support precision pharmacotherapy for doxepin, particularly in the context of antidepressant treatment.\n                  <\/jats:p>","DOI":"10.1007\/s12272-026-01600-5","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:52:02Z","timestamp":1772167922000},"page":"278-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PBPK modeling of the antidepressant doxepin incorporating CYP2D6 genotype for precision pharmacotherapy"],"prefix":"10.1007","volume":"49","author":[{"given":"Joohee","family":"Seok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahyun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Keun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"4","key":"1600_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/00007691-199508000-00010","volume":"17","author":"M Adamczyk","year":"1995","unstructured":"Adamczyk M, Fishpaugh JR, Harrington C (1995) Quantitative determination of E- and Z-doxepin and E- and Z-desmethyldoxepin by high-performance liquid chromatography. Ther Drug Monit 17(4):371\u2013376. https:\/\/doi.org\/10.1097\/00007691-199508000-00010","journal-title":"Ther Drug Monit"},{"key":"1600_CR2","unstructured":"Almasi A, Patel P, Meza CE (2024) Doxepin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542306\/?utm_source=chatgpt.com, Accessed on Jan 20, 2026"},{"issue":"1","key":"1600_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010050","volume":"17","author":"GM Asnis","year":"2015","unstructured":"Asnis GM, Thomas M, Henderson MA (2015) Pharmacotherapy treatment options for insomnia: a primer for clinicians. Int J Mol Sci 17(1):50. https:\/\/doi.org\/10.3390\/ijms17010050","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1600_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s12272-020-01293-4","volume":"43","author":"JW Bae","year":"2020","unstructured":"Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ (2020) Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res 43(11):1207\u20131213. https:\/\/doi.org\/10.1007\/s12272-020-01293-4","journal-title":"Arch Pharm Res"},{"issue":"6","key":"1600_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1055\/s-2004-832687","volume":"37","author":"P Baumann","year":"2004","unstructured":"Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, M\u00fcller-Oerlinghausen B, Rao ML, Riederer P, Zernig G (2004) The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37(6):243\u2013265. https:\/\/doi.org\/10.1055\/s-2004-832687","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"1600_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","volume":"53","author":"L Bertilsson","year":"2002","unstructured":"Bertilsson L, Dahl ML, Dal\u00e9n P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53(2):111\u2013122. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01548.x","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1600_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41431-023-01347-3","volume":"32","author":"L Beunk","year":"2024","unstructured":"Beunk L, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, Houwink EJF, Risselada A, Rongen G, van Schaik RHN, Swen JJ, Touw D, van Westrhenen R, Deneer VHM, van der Weide J (2024) Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet 32(3):278\u2013285. https:\/\/doi.org\/10.1038\/s41431-023-01347-3","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"1600_CR8","first-page":"113","volume":"31","author":"MG Bogaert","year":"1981","unstructured":"Bogaert MG, Rosseel MT, Deberdt R, Vranckx C (1981) Plasma levels of the cis- and trans-isomers of doxepin and desmethyldoxepin after administration of doxepin to patients. Arzneimittelforschung 31(1):113\u2013115","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"1600_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/a-1288-1061","volume":"54","author":"CA Bousman","year":"2021","unstructured":"Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, Asl BB, Bishop JR, Burmeister M, Chaumette B, Chen LS, Cordner ZA, Deckert J, Degenhardt F, DeLisi LE, Folkersen L, Kennedy JL, Klein TE, McClay JL, McMahon FJ, Musil R, Saccone NL, Sangkuhl K, Stowe RM, Tan EC, Tiwari AK, Zai CC, Zai G, Zhang J, Gaedigk A, M\u00fcller DJ (2021) Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry 54(1):5\u201317. https:\/\/doi.org\/10.1055\/a-1288-1061","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"1600_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","volume":"114","author":"CA Bousman","year":"2023","unstructured":"Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Rua\u00f1o G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR (2023) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther 114(1):51\u201368. https:\/\/doi.org\/10.1002\/cpt.2903","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1600_CR11","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41431-021-01004-7","volume":"30","author":"J Brouwer","year":"2022","unstructured":"Brouwer J, Nijenhuis M, Soree B, Guchelaar HJ, Swen JJ, van Schaik RHN, Weide JV, Rongen G, Buunk AM, de Boer-Veger NJ, Houwink EJF, van Westrhenen R, Wilffert B, Deneer VHM, Mulder H (2022) Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. Eur J Hum Genet 30(10):1114\u20131120. https:\/\/doi.org\/10.1038\/s41431-021-01004-7","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"1600_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/00003088-199937020-00004","volume":"37","author":"MJ Burke","year":"1999","unstructured":"Burke MJ, Preskorn SH (1999) Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin Pharmacokinet 37(2):147\u2013165. https:\/\/doi.org\/10.2165\/00003088-199937020-00004","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1600_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s12272-018-1075-6","volume":"41","author":"JY Byeon","year":"2018","unstructured":"Byeon JY, Kim YH, Lee CM, Kim SH, Chae WK, Jung EH, Choi CI, Jang CG, Lee SY, Bae JW, Lee YJ (2018) CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Arch Pharm Res 41(9):921\u2013930. https:\/\/doi.org\/10.1007\/s12272-018-1075-6","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1600_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12272-018-1099-y","volume":"42","author":"JY Byeon","year":"2019","unstructured":"Byeon JY, Lee CM, Lee YJ, Kim YH, Kim SH, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY (2019) Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine. Arch Pharm Res 42(2):182\u2013190. https:\/\/doi.org\/10.1007\/s12272-018-1099-y","journal-title":"Arch Pharm Res"},{"issue":"8","key":"1600_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12272-023-01462-1","volume":"46","author":"JY Byeon","year":"2023","unstructured":"Byeon JY, Cho CK, Kang P, Kim SH, Jang CG, Lee SY, Lee YJ (2023) Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone. Arch Pharm Res 46(8):713\u2013721. https:\/\/doi.org\/10.1007\/s12272-023-01462-1","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1600_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling MV, Scott SA, Hertz DL, Guchelaar HJ, Gaedigk A (2020) Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci 13(1):116\u2013124. https:\/\/doi.org\/10.1111\/cts.12692","journal-title":"Clin Transl Sci"},{"issue":"11-12","key":"1600_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s12272-023-01472-z","volume":"46","author":"CK Cho","year":"2023","unstructured":"Cho CK, Kang P, Jang CG, Lee SY, Lee YJ, Choi CI (2023) Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes. Arch Pharm Res 46(11\u201312):939\u2013953. https:\/\/doi.org\/10.1007\/s12272-023-01472-z","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1600_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12272-024-01495-0","volume":"47","author":"CK Cho","year":"2024","unstructured":"Cho CK, Kang P, Jang CG, Lee SY, Lee YJ, Bae JW, Choi CI (2024a) PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine. Arch Pharm Res 47(5):481\u2013504. https:\/\/doi.org\/10.1007\/s12272-024-01495-0","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1600_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12272-023-01478-7","volume":"47","author":"CK Cho","year":"2024","unstructured":"Cho CK, Ko E, Mo JY, Kang P, Jang CG, Lee SY, Lee YJ, Bae JW, Choi CI (2024b) PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes. Arch Pharm Res 47(1):82\u201394. https:\/\/doi.org\/10.1007\/s12272-023-01478-7","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1600_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s12272-023-01476-9","volume":"47","author":"CK Cho","year":"2024","unstructured":"Cho CK, Mo JY, Ko E, Kang P, Jang CG, Lee SY, Lee YJ, Bae JW, Choi CI (2024c) Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism. Arch Pharm Res 47(2):95\u2013110. https:\/\/doi.org\/10.1007\/s12272-023-01476-9","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1600_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12272-024-01531-z","volume":"48","author":"CK Cho","year":"2025","unstructured":"Cho CK, Kang P, Jang CG, Lee YJ, Bae JW, Choi CI, Lee SY (2025) Effects of fluconazole on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes. Arch Pharm Res 48(3):224\u2013233. https:\/\/doi.org\/10.1007\/s12272-024-01531-z","journal-title":"Arch Pharm Res"},{"key":"1600_CR22","first-page":"160","volume-title":"Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology","author":"K Dawkins","year":"1994","unstructured":"Dawkins K, Manji HK, Potter WZ (1994) Pharmacodynamics of Antidepressants. In: Cutler NR, Sramek JJ, Narang PK (eds) Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology. John Wiley and Sons, Hoboken, p 160 (ISBN 978-0-471-95052-3)"},{"issue":"1","key":"1600_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1017\/s1092852900020022","volume":"14","author":"J de Leon","year":"2009","unstructured":"de Leon J, Susce MT, Johnson M, Hardin M, Maw L, Shao A, Allen AC, Chiafari FA, Hillman G, Nikoloff DM (2009) DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr 14(1):19\u201334. https:\/\/doi.org\/10.1017\/s1092852900020022","journal-title":"CNS Spectr"},{"issue":"2","key":"1600_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s0731-7085(02)00319-9","volume":"30","author":"C Dell'Aquila","year":"2002","unstructured":"Dell\u2019Aquila C (2002) Separation of tricyclic antidepressants by capillary zone electrophoresis with N,N,N\u2019,N\u2019-tetramethyl-1,3-butanediamine (TMBD) as an effective electrolyte additive. J Pharm Biomed Anal 30(2):341\u2013350. https:\/\/doi.org\/10.1016\/s0731-7085(02)00319-9","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"1600_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s002130050260","volume":"131","author":"M Deuschle","year":"1997","unstructured":"Deuschle M, H\u00e4rtter S, Hiemke C, Standhardt H, Heuser I (1997) Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. Psychopharmacology 131(1):19\u201322. https:\/\/doi.org\/10.1007\/s002130050260","journal-title":"Psychopharmacology"},{"issue":"5","key":"1600_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/clinchem\/34.5.863","volume":"34","author":"L Ereshefsky","year":"1988","unstructured":"Ereshefsky L, Tran-Johnson T, Davis CM, LeRoy A (1988) Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine--new data and review. Clin Chem 34(5):863\u2013880","journal-title":"Clin Chem"},{"issue":"4","key":"1600_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/clpt.1983.206","volume":"34","author":"RD Faulkner","year":"1983","unstructured":"Faulkner RD, Pitts WM, Lee CS, Lewis WA, Fann WE (1983) Multiple-dose doxepin kinetics in depressed patients. Clin Pharmacol Ther 34(4):509\u2013515. https:\/\/doi.org\/10.1038\/clpt.1983.206","journal-title":"Clin Pharmacol Ther"},{"key":"1600_CR28","unstructured":"FDA (2007) SINEQUAN\u00ae (doxepin HCl) CAPSULES ORAL CONCENTRATE. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/016798s054,017516s023lbl.pdf. Accessed on Jan 20, 2026."},{"key":"1600_CR29","unstructured":"FDA (2014). Doxepin hydrochloride capsules: Prescribing information. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/070791s027lbl.pdf, Accessed on Jan 20, 2026."},{"key":"1600_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.826138","volume":"13","author":"CSM Funk","year":"2022","unstructured":"Funk CSM, Hart XM, Gr\u00fcnder G, Hiemke C, Elsner B, Kreutz R, Riemer TG (2022) Is therapeutic drug monitoring relevant for antidepressant drug therapy? Implications from a systematic review and meta-analysis with focus on moderating factors. Front Psychiatry 13:826138. https:\/\/doi.org\/10.3389\/fpsyt.2022.826138","journal-title":"Front Psychiatry"},{"key":"1600_CR75","doi-asserted-by":"publisher","unstructured":"Geister U, Gaupp M, Arnold P, Schaarschmidt D, Doser K, and Renner J (2001) Bioavailability investigation of two different oral formulations of doxepin. Arzneimittelforschung 51(3):189\u2013196. https:\/\/doi.org\/10.1055\/s-0031-1300024","DOI":"10.1055\/s-0031-1300024"},{"issue":"6","key":"1600_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/00008571-199912000-00006","volume":"9","author":"EU Griese","year":"1999","unstructured":"Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M (1999) Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 9(6):715\u2013723","journal-title":"Pharmacogenetics"},{"issue":"11","key":"1600_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40262-020-00896-w","volume":"59","author":"N Hanke","year":"2020","unstructured":"Hanke N, T\u00fcrk D, Selzer D, Ishiguro N, Ebner T, Wiebe S, M\u00fcller F, Stopfer P, Nock V, Lehr T (2020) A comprehensive whole-body physiologically based pharmacokinetic drug-drug-gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals. Clin Pharmacokinet 59(11):1419\u20131431. https:\/\/doi.org\/10.1007\/s40262-020-00896-w","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1600_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/00008571-200010000-00003","volume":"10","author":"VS Haritos","year":"2000","unstructured":"Haritos VS, Ghabrial H, Ahokas JT, Ching MS (2000) Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenet Genomics 10(7):591\u2013603","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"1600_CR34","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1023\/a:1016478708902","volume":"19","author":"S H\u00e4rtter","year":"2002","unstructured":"H\u00e4rtter S, Tybring G, Friedberg T, Weigmann H, Hiemke C (2002) The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 19(7):1034\u20131037. https:\/\/doi.org\/10.1023\/a:1016478708902","journal-title":"Pharm Res"},{"issue":"5","key":"1600_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/clpt.2013.2","volume":"93","author":"JK Hicks","year":"2013","unstructured":"Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, M\u00fcller DJ, Gaedigk A, Stingl JC (2013) Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93(5):402\u2013408. https:\/\/doi.org\/10.1038\/clpt.2013.2","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1600_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","volume":"102","author":"JK Hicks","year":"2017","unstructured":"Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, M\u00fcller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC (2017) Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 102(1):37\u201344. https:\/\/doi.org\/10.1002\/cpt.597","journal-title":"Clin Pharmacol Ther"},{"key":"1600_CR37","unstructured":"Hindmarsh AC, Reynolds DR, Serban R, Woodward CS, Gardner DJ, Cohen SD, Taylor AG, Peles S, Banks LE, and Shumaker D. (2025) Open systems pharmacology suite manual & copyright. version 11 update 1. https:\/\/docs.open-systems-pharmacology.org\/working-with-pk-sim\/pk-sim-documentation\/pk-sim-quick-guide. Accessed Jan 10, 2026."},{"issue":"8","key":"1600_CR38","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1373\/clinchem.2009.123620","volume":"55","author":"N Hosono","year":"2009","unstructured":"Hosono N, Kato M, Kiyotani K, Mushiroda T, Takata S, Sato H, Amitani H, Tsuchiya Y, Yamazaki K, Tsunoda T, Zembutsu H, Nakamura Y, Kubo M (2009) Cyp2d6 genotyping for functional-gene dosage analysis by allele copy number detection. Clin Chem 55(8):1546\u20131554. https:\/\/doi.org\/10.1373\/clinchem.2009.123620","journal-title":"Clin Chem"},{"issue":"2","key":"1600_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00007691-199003000-00003","volume":"12","author":"PD Hrdina","year":"1990","unstructured":"Hrdina PD, Bakish D, Swenson S, Lapierre YD (1990) Cis- and trans-isomers of doxepin and desmethyldoxepin in the plasma of depressed patients treated with doxepin. Ther Drug Monit 12(2):129\u2013133. https:\/\/doi.org\/10.1097\/00007691-199003000-00003","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1600_CR40","first-page":"25","volume":"16","author":"PD Hrdina","year":"1991","unstructured":"Hrdina PD, Bakish D, Swenson S, Lapierre YD (1991) Prediction of steady-state plasma levels of doxepin and imipramine from single dose levels in depressed outpatients. J Psychiatry Neurosci 16(1):25\u201329","journal-title":"J Psychiatry Neurosci"},{"issue":"5","key":"1600_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/jmr.3098","volume":"37","author":"H Kaneko","year":"2024","unstructured":"Kaneko H, Korenaga R, Nakamura R, Kawai S, Ando T, Shiroishi M (2024) Binding characteristics of the doxepin E\/Z-isomers to the histamine H1 receptor revealed by receptor-bound ligand analysis and molecular dynamics study. J Mol Recognit 37(5):e3098. https:\/\/doi.org\/10.1002\/jmr.3098","journal-title":"J Mol Recognit"},{"issue":"4","key":"1600_CR42","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S2222-1808(13)60080-8","volume":"3","author":"J Katwala","year":"2013","unstructured":"Katwala J, Kumar AK, Sejpal JJ, Terrence M, Mishra M (2013) Therapeutic rationale for low dose doxepin in insomnia patients. Asian Pac J Trop Dis 3(4):331\u2013336. https:\/\/doi.org\/10.1016\/S2222-1808(13)60080-8","journal-title":"Asian Pac J Trop Dis"},{"issue":"8","key":"1600_CR43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/01.fpc.0000167331.30905.9e","volume":"15","author":"J Kirchheiner","year":"2005","unstructured":"Kirchheiner J, Henckel H-B, Franke L, Meineke I, Tzvetkov M, Uebelhack R, Roots I, Brockm\u00f6ller J (2005) Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics 15(8):579\u2013587. https:\/\/doi.org\/10.1097\/01.fpc.0000167331.30905.9e","journal-title":"Pharmacogenet Genomics"},{"key":"1600_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-025-02008-3","author":"K Kleine Schaars","year":"2026","unstructured":"Kleine Schaars K, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, Houwink EJF, Risselada A, Rongen GAPJM, van Schaik RHN, Swen JJ, Touw D, Deneer VHM, van Westrhenen R (2026) Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and CYP2C19 and tricyclic antidepressants. Eur J Hum Genet. https:\/\/doi.org\/10.1038\/s41431-025-02008-3","journal-title":"Eur J Hum Genet"},{"key":"1600_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105538","volume":"167","author":"Z Kordou","year":"2021","unstructured":"Kordou Z, Skokou M, Tsermpini EE, Chantratita W, Fukunaga K, Mushiroda T, Patrinos GP, Koromina M (2021) Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data. Pharmacol Res 167:105538. https:\/\/doi.org\/10.1016\/j.phrs.2021.105538","journal-title":"Pharmacol Res"},{"issue":"4","key":"1600_CR46","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/00004714-200108000-00011","volume":"21","author":"S Leucht","year":"2001","unstructured":"Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W (2001) Doxepin plasma concentrations: is there really a therapeutic range? J Clin Psychopharmacol 21(4):432\u2013439. https:\/\/doi.org\/10.1097\/00004714-200108000-00011","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1600_CR47","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.yrtph.2008.01.011","volume":"50","author":"G Loizou","year":"2008","unstructured":"Loizou G (2008) Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul Toxicol Pharmacol 50(3):400\u2013411. https:\/\/doi.org\/10.1016\/j.yrtph.2008.01.011","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"1600_CR48","first-page":"29","volume":"96","author":"E Matheson","year":"2017","unstructured":"Matheson E, Hainer BL (2017) Insomnia: pharmacologic therapy. Am Fam Physician 96(1):29\u201335","journal-title":"Am Fam Physician"},{"issue":"5","key":"1600_CR49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/bf00314865","volume":"42","author":"KK Midha","year":"1992","unstructured":"Midha KK, Hubbard JW, McKay G, Hawes EM, Korchinski ED, Gurnsey T, Cooper JK, Schwede R (1992) Stereoselective pharmacokinetics of doxepin isomers. Eur J Clin Pharmacol 42(5):539\u2013544. https:\/\/doi.org\/10.1007\/bf00314865","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1600_CR50","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/cpt.1032","volume":"104","author":"M Ning","year":"2018","unstructured":"Ning M, Duarte JD, Rubin LH, Jeong H (2018) CYP2D6 protein level is the major contributor to interindividual variability in CYP2D6-mediated drug metabolism in healthy human liver tissue. Clin Pharmacol Ther 104(5):974\u2013982. https:\/\/doi.org\/10.1002\/cpt.1032","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1600_CR51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12272-024-01528-8","volume":"48","author":"HJ Park","year":"2025","unstructured":"Park HJ, Lee SH, Kang P, Cho CK, Jang CG, Lee SY, Lee YJ, Bae JW, Choi CI (2025) Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19. Arch Pharm Res 48(3):234\u2013250. https:\/\/doi.org\/10.1007\/s12272-024-01528-8","journal-title":"Arch Pharm Res"},{"key":"1600_CR52","unstructured":"PharmGKB. (2024) \"PharmGKB. Doxepin metabolic pathway. [Online] https:\/\/www.pharmgkb.org\/pathway\/PA165981686. Accessed 13Apr2025"},{"issue":"3","key":"1600_CR53","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bcpt.12590","volume":"119","author":"P Pietarinen","year":"2016","unstructured":"Pietarinen P, Tornio A, Niemi M (2016) High frequency of CYP2D6 ultrarapid metabolizer genotype in the Finnish population. Basic Clin Pharmacol Toxicol 119(3):291\u2013296. https:\/\/doi.org\/10.1111\/bcpt.12590","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"1600_CR54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00003495-197713030-00001","volume":"13","author":"RM Pinder","year":"1977","unstructured":"Pinder RM, Brogden RN, Speight TM, Avery GS (1977) Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 13(3):161\u2013218. https:\/\/doi.org\/10.2165\/00003495-197713030-00001","journal-title":"Drugs"},{"issue":"1","key":"1600_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/JCP.0b013e318192e4c1","volume":"29","author":"S Preskorn","year":"2009","unstructured":"Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI (2009) Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 29(1):39\u201343. https:\/\/doi.org\/10.1097\/JCP.0b013e318192e4c1","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1600_CR56","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ygeno.2008.05.004","volume":"92","author":"S Qin","year":"2008","unstructured":"Qin S, Shen L, Zhang A, Xie J, Shen W, Chen L, Tang J, Xiong Y, Yang L, Shi Y, Feng G, He L, Xing Q (2008) Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. Genomics 92(3):152\u2013158. https:\/\/doi.org\/10.1016\/j.ygeno.2008.05.004","journal-title":"Genomics"},{"issue":"1","key":"1600_CR57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0022-3565(25)21446-X","volume":"230","author":"E Richelson","year":"1984","unstructured":"Richelson E, Nelson A (1984) Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230(1):94\u2013102","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1600_CR58","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95(6):1238\u20131257. https:\/\/doi.org\/10.1002\/jps.20502","journal-title":"J Pharm Sci"},{"issue":"5","key":"1600_CR59","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0006-2952(98)00268-8","volume":"57","author":"AD Rodrigues","year":"1999","unstructured":"Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57(5):465\u2013480. https:\/\/doi.org\/10.1016\/S0006-2952(98)00268-8","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"1600_CR60","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/1715163514543856","volume":"147","author":"CH Rojas-Fernandez","year":"2014","unstructured":"Rojas-Fernandez CH, Chen Y (2014) Use of ultra-low-dose (\u22646 mg) doxepin for treatment of insomnia in older people. Canadian Pharmacists Journal \/ Revue des Pharmaciens Du Canada 147(5):281\u2013289. https:\/\/doi.org\/10.1177\/1715163514543856","journal-title":"Canadian Pharmacists Journal \/ Revue des Pharmaciens Du Canada"},{"issue":"11","key":"1600_CR61","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/sleep\/30.11.1555","volume":"30","author":"T Roth","year":"2007","unstructured":"Roth T, Rogowski R, Hull S, Schwartz H, Koshorek G, Corser B, Seiden D, Lankford A (2007) Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 30(11):1555\u20131561. https:\/\/doi.org\/10.1093\/sleep\/30.11.1555","journal-title":"Sleep"},{"issue":"11","key":"1600_CR62","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.clinthera.2016.09.010","volume":"38","author":"JL Schroeck","year":"2016","unstructured":"Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, Mergenhagen KA (2016) Review of safety and efficacy of sleep medicines in older adults. Clin Ther 38(11):2340\u20132372. https:\/\/doi.org\/10.1016\/j.clinthera.2016.09.010","journal-title":"Clin Ther"},{"key":"1600_CR74","unstructured":"Schioppi L, Dorsey BT, Skinner M, Carter J, Mansbach R, Jochelson P, Rogowski RL, Casseday CB, Perry M, Knox B (2018) US Patent 9907780B2"},{"issue":"7354","key":"1600_CR63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature10236","volume":"475","author":"T Shimamura","year":"2011","unstructured":"Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, Abagyan R, Cherezov V, Liu W, Han GW, Kobayashi T, Stevens RC, Iwata S (2011) Structure of the human histamine H1 receptor complex with doxepin. Nature 475(7354):65\u201370. https:\/\/doi.org\/10.1038\/nature10236","journal-title":"Nature"},{"issue":"8","key":"1600_CR64","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1517\/13543784.16.8","volume":"16","author":"H Singh","year":"2007","unstructured":"Singh H, Becker PM (2007) Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs 16(8):1295\u20131305. https:\/\/doi.org\/10.1517\/13543784.16.8","journal-title":"Expert Opin Investig Drugs"},{"key":"1600_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcis.2015.04.029","volume":"453","author":"T Thiebault","year":"2015","unstructured":"Thiebault T, Gu\u00e9gan R, Boussafir M (2015) Adsorption mechanisms of emerging micro-pollutants with a clay mineral: case of tramadol and doxepine pharmaceutical products. J Colloid Interface Sci 453:1\u20138. https:\/\/doi.org\/10.1016\/j.jcis.2015.04.029","journal-title":"J Colloid Interface Sci"},{"issue":"2","key":"1600_CR66","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1600-0773.1982.tb01008.x","volume":"51","author":"R Virtanen","year":"1982","unstructured":"Virtanen R, Iisalo E, Irjala K (1982) Protein binding of doxepin and desmethyldoxepin. Acta Pharmacol Toxicol (Copenh) 51(2):159\u2013164. https:\/\/doi.org\/10.1111\/j.1600-0773.1982.tb01008.x","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"issue":"6","key":"1600_CR67","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/00008571-200108000-00004","volume":"11","author":"YJ Wan","year":"2001","unstructured":"Wan YJ, Poland RE, Han G, Konishi T, Zheng YP, Berman N, Lin KM (2001) Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 11(6):489\u2013499. https:\/\/doi.org\/10.1097\/00008571-200108000-00004","journal-title":"Pharmacogenetics"},{"issue":"2","key":"1600_CR68","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00004714-198204000-00009","volume":"2","author":"NG Ward","year":"1982","unstructured":"Ward NG, Bloom VL, Wilson L, Raskind M, Raisys VA (1982) Doxepin plasma levels and therapeutic response in depression: preliminary findings. J Clin Psychopharmacol 2(2):126\u2013128","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1600_CR69","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34(3):401\u2013431. https:\/\/doi.org\/10.1007\/s10928-007-9053-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"1600_CR70","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/psp4.12511","volume":"9","author":"JG Wojtyniak","year":"2020","unstructured":"Wojtyniak JG, Britz H, Selzer D, Schwab M, Lehr T (2020) Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 9(6):322\u2013331. https:\/\/doi.org\/10.1002\/psp4.12511","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1600_CR71","volume-title":"Handbook of aqueous solubility data","author":"SH Yalkowsky","year":"2010","unstructured":"Yalkowsky SH, He Y, Jain P (2010) Handbook of aqueous solubility data. CRC Press, Boca Raton"},{"issue":"7","key":"1600_CR72","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/00498250210131879","volume":"32","author":"JH Yan","year":"2002","unstructured":"Yan JH, Hubbard JW, McKay G, Korchinski ED, Midha KK (2002) Absolute bioavailability and stereoselective pharmacokinetics of doxepin. Xenobiotica 32(7):615\u2013623. https:\/\/doi.org\/10.1080\/00498250210131879","journal-title":"Xenobiotica"},{"key":"1600_CR73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.smrv.2014.06.001","volume":"19","author":"WF Yeung","year":"2015","unstructured":"Yeung WF, Chung KF, Yung KP, Ng TH (2015) Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev 19:75\u201383. https:\/\/doi.org\/10.1016\/j.smrv.2014.06.001","journal-title":"Sleep Med Rev"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-026-01600-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-026-01600-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-026-01600-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:37:49Z","timestamp":1773815869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-026-01600-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s12272-026-01600-5","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YJ Lee is an Associate Editor of this journal Archives of Pharmacal Research but this position did not affect the peer-review process and editorial decision. Any other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}